Influence of solute carriers on the pharmacokinetics of CYP3A4 probes

Clinical Pharmacology and Therapeutics

Volumn 84, Issue 6, 2008, Pages 704-709

  Franke, R M ^a   Baker, S D ^a   Mathijssen, R H ^b   Schuetz, E G ^a   Sparreboom, A ^a,b  

^a ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

^b ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

CARBON 14; COMPLEMENTARY RNA; CYTOCHROME P450 3A4; DNA; ERYTHROMYCIN; MIDAZOLAM; RIFAMPICIN;

ADULT; AGED; ANIMAL CELL; ARTICLE; CANCER CHEMOTHERAPY; CANCER PATIENT; CELL STRAIN HEK293; CLINICAL ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; DNA SEQUENCE; DRUG METABOLISM; DRUG UPTAKE; ENZYME ACTIVITY; ENZYME SUBSTRATE; GENETIC POLYMORPHISM; GENOTYPE; HAPLOTYPE; HUMAN; HUMAN CELL; ISOTOPE LABELING; LIVER METABOLISM; NONHUMAN; OOCYTE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; XENOPUS LAEVIS;

BREATH TESTS; CYTOCHROME P-450 CYP3A; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; ERYTHROMYCIN; FEMALE; GENOTYPE; HAPLOTYPES; HEPATOCYTES; HETEROZYGOTE; HUMANS; MALE; MIDAZOLAM; MOLECULAR PROBE TECHNIQUES; NEOPLASMS; ORGANIC ANION TRANSPORTERS, SODIUM-INDEPENDENT; PHARMACOGENETICS; RISK FACTORS; SENSITIVITY AND SPECIFICITY;

EID: 56549111157     PISSN: 00099236     EISSN: 15326535     Source Type: Journal    
DOI: 10.1038/clpt.2008.94     Document Type: Article

References (38)

1. Cummins, C.L., Wu, C.Y. & Benet, L.Z. Sex-related differences in the clearance of cytochrome P450 3A4 substrates may be caused by P-glycoprotein. Clin. Pharmacol. Ther. 72, 474-489 (2002).
2. Watkins, P.B. Noninvasive tests of CYP3A enzymes. Pharmacogenetics 4, 171-184 (1994).
3. Watkins, P.B., Murray, S.A., Winkelman, L.G., Heuman, D.M., Wrighton, S.A. & Guzelian, P.S. Erythromycin breath test as an assay of glucocorticoid-inducible liver cytochromes P-450. Studies in rats and patients. J. Clin. Invest. 83, 688-697 (1989).
4. Watkins, P.B. Breath tests as noninvasive assays of P450s. Methods Enzymol. 206, 517-522 (1991).
5. Kharasch, E.D., Thummel, K.E. & Watkins, P.B. CYP3A probes can quantitatively predict the in vivo kinetics of other CYP3A substrates and can accurately assess CYP3A induction and inhibition. Mol. Interv. 5, 151-153 (2005).
6. Benet, L.Z. There are no useful CYP3A probes that quantitatively predict the in vivo kinetics of other CYP3A substrates and no expectation that one will be found. Mol. Interv. 5, 79-83 (2005).
7. Lam, J.L., Okochi, H., Huang, Y. & Benet, L.Z. In vitro and in vivo correlation of hepatic transporter effects on erythromycin metabolism: characterizing the importance of transporter-enzyme interplay. Drug Metab. Dispos. 34, 1336-1344 (2006).
8. Frassetto, L.A., Poon, S., Tsourounis, C., Valera, C. & Benet, L.Z. Effects of uptake and efflux transporter inhibition on erythromycin breath test results. Clin. Pharmacol. Ther. 81, 828-832 (2007).
9. Fattinger, K., Cattori, V., Hagenbuch, B., Meier, P.J. & Stieger, B. Rifamycin SV and rifampicin exhibit differential inhibition of the hepatic rat organic anion transporting polypeptides, Oatp1 and Oatp2. Hepatology 32, 82-86 (2000).
10. Vavricka, S.R., Van Montfoort, J., Ha, H.R., Meier, P.J. & Fattinger, K. Interactions of rifamycin SV and rifampicin with organic anion uptake systems of human liver. Hepatology 36, 164-172 (2002).
11. König, J., Cui, Y., Nies, A.T. & Keppler, D. Localization and genomic organization of a new hepatocellular organic anion transporting polypeptide. J. Biol. Chem. 275, 23161-23168 (2000).
12. Smith, N.F. et al. Variants in the SLCO1B3 gene: interethnic distribution and association with paclitaxel pharmacokinetics. Clin. Pharmacol. Ther. 81, 76-82 (2007).
13. Tsujimoto, M., Hirata, S., Dan, Y., Ohtani, H. & Sawada, Y. Polymorphisms and linkage disequilibrium of the OATP8 (OATP1B3) gene in Japanese subjects. Drug Metab. Pharmacokinet. 21, 165-169 (2006).
14. McCrea, J. et al. Concurrent administration of the erythromycin breath test (EBT) and oral midazolam as in vivo probes for CYP3A activity. J. Clin. Pharmacol. 39, 1212-1220 (1999).
15. Prueksaritanont, T. et al. Simvastatin does not affect CYP3A activity, quantified by the erythromycin breath test and oral midazolam pharmacokinetics, in healthy male subjects. J. Clin. Pharmacol. 40, 1274-1279 (2000).
16. Veronese, M.L., Gillen, L.P., Dorval, E.P., Hauck, W.W., Waldman, S.A. & Greenberg, H.E. Effect of mibefradil on CYP3A4 in vivo. J. Clin. Pharmacol. 43, 1091-1100 (2003).
17. Veronese, M.L. et al. Exposure-dependent inhibition of intestinal and hepatic CYP3A4 in vivo by grapefruit juice. J. Clin. Pharmacol. 43, 831-839 (2003).
18. Floyd, M.D. et al. Genotype-phenotype associations for common CYP3A4 and CYP3A5 variants in the basal and induced metabolism of midazolam in European- and African-American men and women. Pharmacogenetics 13, 595-606 (2003).
19. Adams, M., Pieniaszek, H.J. Jr., Gammaitoni, A.R. & Ahdieh, H. Oxymorphone extended release does not affect CYP2C9 or CYP3A4 metabolic pathways. J. Clin. Pharmacol. 45, 337-345 (2005).
20. Kurnik, D., Wood, A.J. & Wilkinson, G.R. The erythromycin breath test reflects P-glycoprotein function independently of cytochrome P450 3A activity. Clin. Pharmacol. Ther. 80, 228-234 (2006).
21. Kinirons, M.T. et al. Failure of erythromycin breath test to correlate with midazolam clearance as a probe of cytochrome P4503A. Clin. Pharmacol. Ther. 66, 224-231 (1999).
22. Masica, A.L., Mayo, G. & Wilkinson, G.R. In vivo comparisons of constitutive cytochrome P450 3A activity assessed by alprazolam, triazolam, and midazolam. Clin. Pharmacol. Ther. 76, 341-349 (2004).
23. Lown, K.S. et al. The erythromycin breath test predicts the clearance of midazolam. Clin. Pharmacol. Ther. 57, 16-24 (1995).
24. Gorski, J.C., Hall, S.D., Jones, D.R., VandenBranden, M. & Wrighton, S.A. Regioselective biotransformation of midazolam by members of the human cytochrome P450 3A (CYP3A) subfamily. Biochem. Pharmacol. 47, 1643-1653 (1994).
25. Wrighton, S.A. et al. Studies on the expression and metabolic capabilities of human liver cytochrome P450IIIA5 (HLp3). Mol. Pharmacol. 38, 207-213 (1990).
26. Kronbach, T., Mathys, D., Umeno, M., Gonzalez, F.J. & Meyer, U.A. Oxidation of midazolam and triazolam by human liver cytochrome P450IIIA4. Mol. Pharmacol. 36, 89-96 (1989).
27. Amidon, G.L., Lennernäs, H., Shah, V.P. & Crison, J.R. A theoretical basis for a biopharmaceutic drug classification: the correlation of in vitro drug product dissolution and in vivo bioavailability. Pharm. Res. 12, 413-420 (1995).
28. Wu, C.Y. & Benet, L.Z. Predicting drug disposition via application of BCS: transport/absorption/elimination interplay and development of a biopharmaceutics drug disposition classification system. Pharm. Res. 22, 11-23 (2005).
29. Gharaibeh, M.N., Gillen, L.P., Osborne, B., Schwartz, J.I. & Waldman, S.A. Effect of multiple doses of rifampin on the [14C N-methyl] erythromycin breath test in healthy male volunteers. J. Clin. Pharmacol. 38, 492-495 (1998).
30. Letschert, K., Keppler, D. & König, J. Mutations in the SLCO1B3 gene affecting the substrate specificity of the hepatocellular uptake transporter OATP1B3 (OATP8). Pharmacogenetics 14, 441-452 (2004).
31. Mathijssen, R.H. et al. Prediction of irinotecan pharmacokinetics by use of cytochrome P450 3A4 phenotyping probes. J. Natl. Cancer Inst. 96, 1585-1592 (2004).
32. Baker, S.D. et al. Factors affecting cytochrome P-450 3A activity in cancer patients. Clin. Cancer Res. 10, 8341-8350 (2004).
33. Rivory, L.P. et al. Optimizing the erythromycin breath test for use in cancer patients. Clin. Cancer Res. 6, 3480-3485 (2000).
34. Rivory, L.P., Slaviero, K.A., Hoskins, J.M. & Clarke, S.J. The erythromycin breath test for the prediction of drug clearance. Clin. Pharmacokinet. 40, 151-158 (2001).
35. Schaid, D.J., McDonnell, S.K., Wang, L., Cunningham, J.M. & Thibodeau, S.N. Caution on pedigree haplotype inference with software that assumes linkage equilibrium. Am. J. Hum. Genet. 71, 992-995 (2002).
36. Hayer-Zillgen, M., Brüss, M. & Bönisch, H. Expression and pharmacological profile of the human organic cation transporters hOCT1, hOCT2 and hOCT3. Br. J. Pharmacol. 136, 829-836 (2002).
37. Tahara, H., Kusuhara, H., Maeda, K., Koepsell, H., Fuse, E. & Sugiyama, Y. Inhibition of oat3-mediated renal uptake as a mechanism for drug-drug interaction between fexofenadine and probenecid. Drug Metab. Dispos. 34, 743-747 (2006).
38. Yasuda, K., Lan, L.B., Sanglard, D., Furuya, K., Schuetz, J.D. & Schuetz, E.G. Interaction of cytochrome P450 3A inhibitors with P-glycoprotein. J. Pharmacol. Exp. Ther. 303, 323-332 (2002).